1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Scandion Oncology A/S

Scandion Oncology A/S

SCOL.ST
Scandion Oncology A/SSE flagStockholm Stock Exchange
0.00
SEK
+0.00
- -
962,520.00Market Cap
Scandion Oncology A/S
SCOL.ST
(Stockholm Stock Exchange)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
-0.24
-0.25
-0.16
-0.49
-0.57
-0.96
-0.16
-0.17
Basic EPS, GAAP
- -
-0.39
-0.21
-0.16
-0.47
-0.52
-1.24
-0.12
-0.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.25
-0.4
-0.33
-0.82
-1.21
-4.96
-0.96
-1.06
Book Value per Share
- -
0.37
0.37
1.47
0.99
0.52
0.76
0.04
0.04
Tangible Book Value per Share
- -
34
50
106
106
134
41
235
212
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
1
1
1
- -
1
Depreciation Expense
- -
-8
-12
-17
-52
-77
-39
-37
-37
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
13
18
156
103
69
30
8
8
Working Capital
- -
- -
- -
- -
- -
1
- -
- -
- -
LT Debt
1
13
18
156
105
70
31
8
8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
232
232
235
Market Capitalization
30
18
10

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
34
23
18
Cash, Cash Equivalents & STI
27
15
13
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
5
10
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
111.03%
-73.43%
Free Cash Flow
- -
45.16%
-45.69%
Net Income, GAAP
- -
47.06%
-6.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.12
-0.22
-0.19
- -
-0.57
2023
-0.07
-0.07
-0.08
-0.08
-0.96
2024
-0.06
-0.03
-0.03
-0.06
-0.16

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Hoth Therapeutics, Inc. (HOTH)
Advicenne S.A. (ADVIC.PA)
StemCell Institute Inc. (7096.T)
Hansa Biopharma AB (publ) (0RC7.L)
Lifecome Biochemistry Co.,Ltd. (002868.SZ)
Veradermics, Incorporated (MANE)
Business
Scandion Oncology A/S is a clinical-stage biotechnology company specializing in developing novel therapeutics to overcome cancer drug resistance. The company's core product is SCO-101, an oral add-on therapy designed to enhance the efficacy of standard chemotherapy by inhibiting drug efflux pumps, specifically targeting ABCG2 and UGT1A1 mechanisms associated with chemotherapy resistance. SCO-101 is under clinical investigation in Phase IIa for metastatic colorectal cancer (CORIST trial) and Phase Ib for unresectable or metastatic pancreatic cancer (PANTAX trial), with preclinical evaluations ongoing for gastric cancer and solid tumors. Scandion also develops SCO-201, a preclinical candidate aimed at treating solid tumors and HIV. Founded in 2017 and headquartered in Copenhagen, Denmark, the company operates primarily within oncology pharmaceuticals and biopharmaceuticals development. In recent major developments, Scandion Oncology has entered voluntary solvent liquidation as of 2025 and has applied for delisting from Nasdaq First North Growth Market Sweden. The company intensifies its partnering and business development efforts, collaborating with investment banking firms to seek strategic alliances and partnerships in the first half of 2025 aimed at advancing further clinical development and commercialization of SCO-101. These efforts follow positive Phase IIa clinical trial results demonstrating SCO-101's efficacy in improving chemotherapy outcomes in drug-resistant metastatic colorectal cancer. The company also completed a rights issue earlier in 2024 to secure funding for its ongoing operations and strategic initiatives. Scandion's focus remains on developing first-in-class medicines that specifically target molecular mechanisms of drug resistance in cancer treatment with the aim of improving patient outcomes worldwide.